期刊文献+

胸腺瘤WHO分型和Masaoka分期的影响因素分析 被引量:4

An analysis of influencing factors for WHO classification and Masaoka stage of thymoma
原文传递
导出
摘要 目的分析胸腺瘤WHO分型和Masaoka分期的影响因素。方法96例经手术切除的胸腺瘤患者,根据WHO分型分为良性(A、AB型,38例)和恶性(B1、B2、B3及C型,58例),根据Masaoka分期分为早中期(Ⅰ、Ⅱ期,71例)和晚期(Ⅲ、Ⅳ期,25例)。分析胸腺瘤WHO分型和Masaoka分期与临床指标的关系,采用logistic回归分析胸腺瘤WHO分型和Masaoka分期的影响因素。结果与良性胸腺瘤患者比较,恶性胸腺瘤患者年龄较小,重症肌无力比例较高(P<0.05)。早中期和晚期胸腺瘤患者肿瘤最大横径、BMI和淋巴细胞计数比较有统计学差异(P<0.05)。多因素logistic回归分析发现,重症肌无力和Masaoka分期晚期是恶性胸腺瘤的独立危险因素,年龄较大是其保护性因素(P<0.05)。淋巴细胞计数较高是晚期胸腺瘤的保护性因素(P<0.05)。结论年龄、Masaoka分期、重症肌无力是胸腺瘤WHO分型的影响因素,淋巴细胞计数是胸腺瘤患者Masaoka分期的影响因素。 Objective To analyze the influencing factors for WHO classification and Masaoka stage of thymoma.Methods According to WHO classification,96 patients with thymoma underwent surgical resection were divided into benign thymoma(type A and AB,38 cases)and malignant thymoma(type B1,B2,B3 and C,58 cases).According to Masaoka stage,the patients were divided into early and middle thymoma(stageⅠandⅡ,71 cases)and advanced thymoma(stageⅢandⅣ,25 cases).The relationship between WHO classification,Masaoka stage and clinical indicators of thymoma was analyzed.The influencing factors for WHO classification and Masaoka stage of thymoma were analyzed by logistic regression analysis.Results Compared to benign thymoma patients,the malignant thymoma patients had younger age and higher proportion with myasthenia gravis(MG)(P<0.05).The maximum tumor diameter,BMI and lymphocyte count were significantly different between the early and middle patients and advanced patients(P<0.05).Multivarite logistic regression analysis showed that MG and advanced thymoma were the independent risk factors and older age was the protective factor for malignant thymoma(P<0.05).High lymphocyte count was the protective factor for advanced thymoma(P<0.05).Conclusion The age,Masaoka stage and MG are the influencing factors for WHO classification of thymoma,and lymphocyte count of thymoma is an influencing factors for Masaoka stage of thymoma.
作者 王立坤 杜天宇 肖旭阳 WANG Likun;DU Tianyu;XIAO Xuyang(Department of Thoracic Surgery,Affiliated First Hospital,Jinzhou Medical Universityy,Jinzhou 121000,CHINA)
出处 《江苏医药》 CAS 2022年第10期1023-1026,共4页 Jiangsu Medical Journal
基金 辽宁省教育厅科学技术研究项目(JYTJCZR201908)。
关键词 胸腺瘤 WHO分型 Masaoka分期 Thymoma WHO classification Masaoka stage
  • 相关文献

参考文献7

二级参考文献29

  • 1田欣伦,朱元珏.胸腺瘤的诊断和预后影响因素分析[J].中华内科杂志,2004,43(9):657-660. 被引量:3
  • 2张清,刘阳,周乃康,孙玉鹗.胸腺瘤的诊断及外科治疗(附120例临床报告)[J].解放军医学杂志,2005,30(2):162-163. 被引量:3
  • 3方文涛,陈文虎,陈岗,何卫中,蒋勇.胸腺上皮肿瘤的外科治疗-204例临床病理分析[J].肿瘤,2005,25(4):377-380. 被引量:15
  • 4FANG Wen-tao,XU Mei-ying,CHEN Gang,CHEN Yong,CHEN Wen-hu.Minimally invasive approaches for histological diagnosis of anterior mediastinal masses[J].Chinese Medical Journal,2007(8):675-679. 被引量:8
  • 5Wang R, Li J, Wang M, et al. Prevalence of myasthenia gravis and as- sociated autoantibodies in paraneoplastic pemphigus and their correla- tions with symptoms and prognosis[ J]. Br J Dermatol, 2014,12(2) : 10 -11.
  • 6Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity[ J]. Eur J Neurol, 2014,30(2) :10 - 11.
  • 7Beydoun SR, Gong H, Ashikian N, et al. Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature[ J]. J Med Case Rep, 2014,13(8) :340.
  • 8Karasaki T, Murakawa T, Nagayama K, et al. New onset of myasthenia gravis 10 years after proton beam therapy for thymoma[ J]. Gen Thorac Cardiovasc Surg, 2014,10 (7) : 156 - 158.
  • 9Maekawa R, Shibuya H, Hideyama T, et al. A case of myasthenia gra- vis with invasive thymoma associated with diffuse panbronchiolitis, alo- pecia, dysgeusia, cholangitis and myositis [ J ]. Rinsho Shinkeigaku, 2014,54(9) :703 -708.
  • 10Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopatho- logic study based on the new World Health Organization classification [J]. J Thorae Cardiovasc Surg, 2003,126(4) :1134 -1140.

共引文献87

同被引文献49

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部